After-Hours Income Review in January (APOL, SQNM, DV, PPHM)

New York, NY -- (SBWIRE) -- 01/09/2013 -- Apollo Group Inc (NASDAQ:APOL), which runs a for-profit education venture, on Tuesday, said that enrolments at the University of Phoenix fell 14 percent in the fiscal first quarter.The company also held out a pessimistic revenue forecast for the year sending its shares down more than 3 percent in after-market trades.Enrolments stood at 319.700 in the September to November quarter.Net income fell 11 percent to $133.5 million from $149.3 million the year before. On a per-share basis, earnings grew to $1.18 per share from $1.14 per share because the company has less stock outstanding.After adjusting for restructuring costs, a litigation credit and other special items, it earned $1.22 per share for the period from continuing operations versus $1.26 per share last year.Revenue dropped 9 percent, to $1.06 billion from $1.17 billion.Analysts had expected the company to earn 90 cents a share on revenue of $1.03 billion.The company expects revenue between $3.65 billion to $3.75 billion for the 2013 fiscal year, which ends in August. Analysts had forecast revenue of $3.78 billion for the year.

Should Investors Buy APOL Now? Free Sign Up Here For APOL Analyst Report

Sequenom, Inc. (NASDAQ:SQNM) shares fell 4.53% to $4.85. The company announced the Company’s participation at the upcoming 31(st) Annual JP Morgan Healthcare Conference, to be hosted at the Westin St. Francis Hotel in San Francisco, CA. On Wednesday, January 9th, Chairman and CEO Harry F. Hixson, Jr., Ph.D, and Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present starting at 11:30 am PT (2:30 pm ET) to provide an overview of and update on the Company.

Will SQNM Bounce Back After yesterday’s Sharp Sell off? Find Out Here

DeVry Inc. Common (NYSE:DV) is -2.08 - -8.24% from the previous close of $25.24. It traded between $22.87 - 24.69 with total traded volume of 1239596 shares. Keep a close eye on DV, as the stock has been showing unusual moves over the past weeks. At Current market price, DV has recovered +27.60% from its 52-week Low of 18.15 and has Pulled back -45.34% from its 52-week high of 42.37.

For a FREE INSTANT ANALYSIS of DV, please visit here

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares dropped 4.12% to $2.33 after the company yesterday provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients. The review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA.

Can PPHM Continue To Move Higher? Find Out Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz